Breaking News

Aenova Bolsters Drug Solubility Solutions with New Technology

Launches hot melt extrusion platform at its Regensburg, Germany facility.

Author Image

By: Charlie Sternberg

Associate Editor

Hot melt extrusion technology can overcome the poor bioavailability of APIs. Image courtesy of Aenova.

Aenova, a leading CDMO, has launched a hot melt extrusion (HME) platform at its Regensburg, Germany facility, enhancing its capabilities to improve the bioavailability of poorly soluble pharmaceutical ingredients. The twin-screw extrusion system, supplied by Leistritz, supports the production of amorphous solid dispersions (ASDs) for active pharmaceutical ingredients (APIs) up to OEB 5 potency levels, addressing a critical need in drug development. Approximately 80% of preclinical drug candid...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters